These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

960 related items for PubMed ID: 27123586

  • 1. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS, Lee YT, Kim KH, Park S, Kwon YM, Lee Y, Ko EJ, Jung YJ, Lee JS, Kim YJ, Lee YN, Kim MC, Cho M, Kang SM.
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [Abstract] [Full Text] [Related]

  • 2. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS, Kim KH, Lee Y, Lee YT, Ko EJ, Park S, Lee JS, Lee BC, Kwon YM, Moore ML, Kang SM.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1031-1039. PubMed ID: 28129031
    [Abstract] [Full Text] [Related]

  • 3. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V, Boigard H, Bhatia B, Fallon JT, Alimova A, Gottlieb P, Galarza JM.
    Clin Vaccine Immunol; 2016 Jun 04; 23(6):451-9. PubMed ID: 27030590
    [Abstract] [Full Text] [Related]

  • 4. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH, Lee YT, Hwang HS, Kwon YM, Kim MC, Ko EJ, Lee JS, Lee Y, Kang SM.
    J Virol; 2015 Nov 04; 89(22):11692-705. PubMed ID: 26355098
    [Abstract] [Full Text] [Related]

  • 5. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.
    Hwang HS, Kwon YM, Lee JS, Yoo SE, Lee YN, Ko EJ, Kim MC, Cho MK, Lee YT, Jung YJ, Lee JY, Li JD, Kang SM.
    Antiviral Res; 2014 Oct 04; 110():115-23. PubMed ID: 25110201
    [Abstract] [Full Text] [Related]

  • 6. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.
    Vaccine; 2015 Oct 05; 33(41):5406-5414. PubMed ID: 26319741
    [Abstract] [Full Text] [Related]

  • 7. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG, Fernando LR, Zhang W, Kamali A, Boukhvalova MS, McGinnes-Cullen L, Morrison TG.
    J Virol; 2019 Dec 01; 93(23):. PubMed ID: 31511382
    [Abstract] [Full Text] [Related]

  • 8. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D, Phan S, DiStefano DJ, Citron MP, Callahan CL, Indrawati L, Dubey SA, Heidecker GJ, Govindarajan D, Liang X, He B, Espeseth AS.
    J Virol; 2017 Jun 01; 91(11):. PubMed ID: 28298602
    [Abstract] [Full Text] [Related]

  • 9. Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.
    Lee JS, Kwon YM, Hwang HS, Lee YN, Ko EJ, Yoo SE, Kim MC, Kim KH, Cho MK, Lee YT, Lee YR, Quan FS, Kang SM.
    Vaccine; 2014 Oct 07; 32(44):5866-74. PubMed ID: 25173478
    [Abstract] [Full Text] [Related]

  • 10. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y, Lee YT, Ko EJ, Kim KH, Hwang HS, Park S, Kwon YM, Kang SM.
    Hum Vaccin Immunother; 2017 Nov 02; 13(11):2594-2605. PubMed ID: 28854003
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.
    Blanco JCG, Pletneva LM, McGinnes-Cullen L, Otoa RO, Patel MC, Fernando LR, Boukhvalova MS, Morrison TG.
    Nat Commun; 2018 May 15; 9(1):1904. PubMed ID: 29765035
    [Abstract] [Full Text] [Related]

  • 12. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, Parrington M, Oomen R, Du RP, Klein M.
    Virology; 2000 Mar 30; 269(1):54-65. PubMed ID: 10725198
    [Abstract] [Full Text] [Related]

  • 13. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS.
    Antiviral Res; 2017 Aug 30; 144():57-69. PubMed ID: 28529001
    [Abstract] [Full Text] [Related]

  • 14. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection.
    Qiao L, Zhang Y, Chai F, Tan Y, Huo C, Pan Z.
    Antiviral Res; 2016 Jul 30; 131():131-40. PubMed ID: 27154395
    [Abstract] [Full Text] [Related]

  • 15. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K, Cayatte C, Bennett AS, Rajani GM, McTamney P, Nacel K, Hostetler L, Cheng L, Ren K, O'Day T, Prince GA, McCarthy MP.
    J Virol; 2017 Apr 15; 91(8):. PubMed ID: 28148790
    [Abstract] [Full Text] [Related]

  • 16. In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
    van Erp EA, van Kasteren PB, Guichelaar T, Ahout IML, de Haan CAM, Luytjes W, Ferwerda G, Wicht O.
    J Virol; 2017 Nov 01; 91(21):. PubMed ID: 28794038
    [Abstract] [Full Text] [Related]

  • 17. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
    Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML.
    Antiviral Res; 2014 Nov 01; 111():129-35. PubMed ID: 25239522
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T, Shafique M, Meijerhof T, Stegmann T, Wilschut J, de Haan A.
    Vaccine; 2013 Apr 19; 31(17):2169-76. PubMed ID: 23499594
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical evaluation of bacterially produced RSV-G protein vaccine: Strong protection against RSV challenge in cotton rat model.
    Fuentes S, Klenow L, Golding H, Khurana S.
    Sci Rep; 2017 Feb 10; 7():42428. PubMed ID: 28186208
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.